Entrada Therapeutics, Inc.
TRDA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001689375
In the last 90 days, Entrada Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 128 institutions reported holding it in 13F filings for Q2 2026, worth $214.4M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Entrada Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 47 | 53 | +6 |
| Shares | 24.7M | 24.9M | +173.2K (+0.7%) |
| Value | $334.2M | $361.0M | +$26.9M (+8.0%) |
New holders (10)
Institutions that held Entrada Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| CHI Advisors LLC | 56,374 | $817.4K | 0.22% |
| HRT Financial LP | 38,395 | $556.0K | 0.01% |
| Marshall Wace, LLP | 17,327 | $251.2K | 0.00% |
| LMR Partners LLP | 13,023 | $188.8K | 0.00% |
| Nuveen Asset Management, LLC | 12,987 | $188.0K | 0.00% |
| Man Group plc | – | $162.5K | 0.00% |
| Y-Intercept (Hong Kong) Ltd | 10,188 | $147.7K | 0.02% |
| Point72 Middle East FZE | 3,441 | $49.9K | 0.00% |
| Point72 Asset Management, L.P. | 2,840 | $41.2K | 0.00% |
| The PNC Financial Services Group, Inc. | 200 | $2.90K | 0.00% |
Sold out (4)
Institutions that held Entrada Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Ergoteles LLC | 14,019 | $189.5K |
| Balyasny Asset Management LLC | 12,132 | $164.0K |
| State of Wisconsin Investment Board | 10,971 | $148.3K |
| Royal Bank of Canada | 28 | $0 |